2024
CNS cell-derived exosome signatures as blood-based biomarkers of neurodegenerative diseases
Park C, Weerakkody J, Schneider R, Miao S, Pitt D. CNS cell-derived exosome signatures as blood-based biomarkers of neurodegenerative diseases. Frontiers In Neuroscience 2024, 18: 1426700. PMID: 38966760, PMCID: PMC11222337, DOI: 10.3389/fnins.2024.1426700.Peer-Reviewed Original ResearchNeurodegenerative diseasesSubtype of extracellular vesiclesDisease-related processesDisease-associated changesCentral nervous systemBlood-based proteinsBiomarkers of neurodegenerative diseasesBlood-brain barrierCell typesExosome populationMolecular cargoExtracellular vesiclesCell of originRNA biomarkersExosome isolationTranslation to clinical useCell-derived exosomesLack of standardized methodologyMolecular contentExosomesBlood-based biomarkersPeripheral bloodCellsExosome signatureMolecular biomarkers
2019
The landscape of myeloid and astrocyte phenotypes in acute multiple sclerosis lesions
Park C, Ponath G, Levine-Ritterman M, Bull E, Swanson EC, De Jager PL, Segal BM, Pitt D. The landscape of myeloid and astrocyte phenotypes in acute multiple sclerosis lesions. Acta Neuropathologica Communications 2019, 7: 130. PMID: 31405387, PMCID: PMC6689891, DOI: 10.1186/s40478-019-0779-2.Peer-Reviewed Original ResearchConceptsMultiple sclerosis lesionsLesion rimAstrocyte phenotypeMyeloid cellsSclerosis lesionsActive multiple sclerosis lesionsAcute multiple sclerosis lesionsGlial activation markersActive MS lesionsNovel therapeutic targetDifferent lesion stagesPredominant cell typeAcute demyelinationDemyelinating lesionsCell typesActivation markersChronic inflammationDistinct myeloidCell-extrinsic factorsGlial cellsPhenotypic subsetsLesion stageGlial phenotypeMS lesionsLesion cells